In breast cancer models, the EGFR inhibitor erlotinib displayed synergy with THZ1 and with the dual cdc7/CDK9 inhibitor PHA-767491 [92, 93], with more lines of evidence suggesting CDK7 and CDK9 inhibitors could sensitise resistant cancer cells to EGFR-targeted therapy [93, 94]. Here, CDK9 is linked to cancer.